Helius Medical Technologies (HSDT) Rating Increased to Buy at BTIG Research
Helius Medical Technologies (OTCMKTS:HSDT) was upgraded by stock analysts at BTIG Research from a “neutral” rating to a “buy” rating in a research report issued on Tuesday.
Helius Medical Technologies stock opened at $8.00 on Tuesday. Helius Medical Technologies has a 1-year low of $7.15 and a 1-year high of $13.20.
Helius Medical Technologies (OTCMKTS:HSDT) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04.
Helius Medical Technologies Company Profile
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.